OUR PURPOSE PIONEERING SCIENCE PATIENTS OUR PEOPLE ENVIRONMENT COMMUNITY REPORTING 33 ADVANCING RESPONSIBLE PRODUCT DEVELOPMENT BIOGEN 2021 YEAR IN REVIEW We continually strive to advance our understanding of biology and the process technologies that can help improve our capabilities and output, and to equip our manufacturing plants with technologies to meet demand for our existing therapies, clinical trials and opportunities in biosimilars. Thorough business continuity planning provides appropriate redundancy in an effort to maintain product availability while minimizing environmental impact. To support our future growth and drug development pipeline, we are expanding our large molecule production capacity by building a large- scale biologics manufacturing facility in Solothurn, Switzerland, which we anticipate will have the capacity to produce up to 10 metric tons of antibodies per year. In the second quarter of 2021 a portion of the facility received a GMP multi-product license from SWISSMEDIC. At our North Carolina facilities, we use an innovative process for early-stage clinical products that increases the flexibility and speed of supplying drugs for clinical studies, and reduces the environmental impacts of the manufacturing process. Þ LEARN MORE ABOUT OUR COMMITMENT TO SUSTAINABLE DRUG DEVELOPMENT Responsible Supplier Program Our emphasis on corporate responsibility extends through our value chain. Biogen suppliers have long been expected to adhere to the principles and practices of ethical business, including our Code of Business Conduct, Human Rights Position Statement and Anti-Slavery and Human Trafficking Statement. Þ RESPONSIBLE SUPPLY CHAIN UPDATE Now, we are taking further steps to formalize and expand our expectations of our suppliers by developing a Responsible Supplier Program, which encompasses a range of ESG issues, notably diversity, equity and inclusion; human rights and fair labor practices; climate commitments; environmental impacts, monitoring and remediation; and transparency and disclosure. This effort is informed by our engagement with the Pharmaceutical Supply Chain Initiative and includes: – Creating a supplier code of conduct: Though our suppliers are expected to do business according to the guiding principles outlined in our Code of Business Conduct, we recognize the need to create a specific set of principles for our suppliers to ensure we are transparent and clear about our business requirements. We are currently in the process of creating a Supplier Code of Conduct that will outline comprehensive criteria for our suppliers across the categories of Ethics, Human Rights and Labor, Health and Safety, and Environment and Management Systems. – Expanding our supplier risk assessment: As part of building our Responsible Supplier Program, we are in the process of expanding our ESG risk screen. We have procured a software that will enable us to simultaneously broaden and deepen our knowledge of our supplier impacts and operations across 21 criteria grouped into four themes: Environment, Labor and Human Rights, Ethics and Sustainable Procurement. The criteria are based on international sustainability standards such as the Global Compact Principles, the International Labour Organization (ILO) conventions, the Global Reporting Initiative (GRI) standards, the ISO 26000 standard and the CERES principles. Our expanded supplier evaluation will enable us to make decisions based on the clearest and more comprehensive information. – Increasing supplier engagement: We are engaging with key suppliers more than ever to identify potential risks, increase transparency and reduce our suppliers’ impacts on climate change. We typically prioritize engaging with partner companies that we do the most business with, but in our effort to decarbonize our value chain, we are instead identifying suppliers with the highest emissions and helping them transition to renewable energy. One way we’re doing this is through Energize program, which we launched this year with nine other pharmaceutical companies to increase access to renewable energy across our supply chains. Þ READ MORE ABOUT OUR PRINCIPLES OF SUSTAINABLE DRUG DEVELOPMENT